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1. Introduction 
The central dogma of biology describes the transfer of biological information from DNA 
through to protein (1). In the first phase, known as transcription, DNA is converted into a 
complementary sequence of messenger RNA (mRNA). This mRNA allows the genetic 
message to be communicated outside of the cell nucleus, to other areas of the cell, where it is 
then translated into protein by ribosomes. Post-transcriptional regulatory events take place 
after an RNA molecule is formed; thereafter the resulting RNA molecule is decoded to 
produce a specific protein. Protein production depends on the length of survival of RNA in 
a cell and the efficiency of its utilizations. 
Since Paterson et al. first demonstrated the utility of nucleic acids in modulating gene 
expression over 30 years ago (2), and in 1978 Zamecnik and Stephenson showed the capacity 
of antisense molecules to inhibit viral replication (3, 4), nucleic acids have emerged as a 
potent force both as R&D tools and as therapeutic agents. 
Indeed, the field of nucleic acid therapeutics has evolved considerably with numerous gene 
targets and methods having been applied in vitro and in vivo in a variety of contexts with 
varying degrees of success. Strategies have included ribozymes, DNA enzymes 
(DNAzymes), antisense oligonucleotides (ASON), decoys, aptamers and siRNAs, all of 
which attenuate gene expression by interfering with cytosolic mRNA or translated protein. 
Currently, a number of these approaches are being evaluated in human and animal trials 
and are poised to offer considerable inroads and additions to our current therapies. 
Ribozymes are catalytically active RNA molecules capable of site-specific cleavage of target 
mRNA and can occur naturally (5). They must contain antisense sequences that will bind to 
the target, and also a sequence that will fold into a structure with ribonuclease activity. Such 
sequences are found in natural hammerhead or hairpin ribozymes. Consequently, 
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ribozymes don’t depend on cellular nucleases for activity (6). The possibility of designing 
ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic 
research and therapeutic applications. 
DNAzymes, like ribozymes, may be perceived as gene-specific molecular scissors. They 
appeared as a development in the study of ribozymes using analogous 
deoxyoligonucleotides, given that catalytic DNA has not been observed in nature (7). All 
existing molecules have been derived by in vitro selection processes similar to those used to 
identify aptamers (see below). The most well-characterized DNAzyme is the “10-23” 
subtype comprising a cation-dependent catalytic core of 15 desoxyribonucleotides that binds 
to and cleaves its target RNA. This core is flanked by complementary binding arms of 6 to 
12 nucleotides in length that confer target mRNA Specificity (8). 
ASONs are single-stranded segments of DNA or RNA generally 15 to 25 nucleotides in 
length designed to mirror specific mRNA sequences and block protein production. 
Although their precise mechanism of action is not fully understood, their function is 
mediated by interaction with target mRNA via hydrogen bonding, blocking translation 
into protein by steric hindrance of ribosomal movement or by activation of endogenous 
RNase H for targeted destruction of the DNA/RNA heteroduplex, resulting in mRNA 
degradation (9). Unmodified ASONs molecules are prone to degradation, and their 
negative charge makes cellular membrane penetration inefficient. As such, these molecules 
have evolved with a variety of modifications that enhance stability and efficacy. Around 50 
clinical studies have used antisense strategies spanning a variety of disease processes, 
including cancer, cardiovascular disease, inflammation and infection (10). Fomivirsen or 
Vitravene®, which targets the immediate-early RNA encoded by human cytomegalovirus 
(CMV) DNA, has been approved by the FDA for use in humans for treatment of CMV 
retinitis (11). 
In contrast to antisense approaches that target mRNA, oligonucleotide decoys are short, 
double-stranded DNA molecules that contain binding elements for a variety of protein 
targets that competitively inhibit promoter binding and gene expression. Although several 
types of decoys have been developed there are important issues to take into account affecting 
the potential clinical use of these molecules, including susceptibility to nuclease degradation, 
propensity to induce a host immunological response, and cell transfection difficulties with 
higher concentration requirements (12). Currently, decoy oligonucleotides are not pursued as 
aggressively as other forms of therapeutic oligonucleotides (13). 
Aptamers are single-stranded oligonucleotides which may fold into complex secondary and 
tertiary structures and bind their target protein with high affinity and specificity, inhibiting 
its function. They are derived by in vitro selection from a combinatorial library of nucleic 
acid sequences (14). Recent developments demonstrate that aptamers are valuable tools for 
diagnostics, purification processes, target validation, drug discovery and therapeutics. 
Macugen® is an aptamer approved by the FDA for treatment of wet AMD (15). 
RNA interference (RNAi) is one of the gene silencing strategies which has received most 
attention in recent times. Its initial discovery in 1998 by Nobel laureates Fire and Mello (16) 
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in Caenorhabditis elegans, led to the subsequent finding of the mechanism in mammalian cells 
and the understanding that it was triggered by small double stranded RNA duplexes of 19-
23 nucleotides in length (17). In the following decade siRNA (short interfering RNA) have 
become widely used tools for silencing gene expression, as they make use of a naturally 
occurring regulatory mechanism that uses these molecules to direct homology-dependent 
mRNA degradation via a multienzymatic complex termed RISC (RNA-induced silencing 
complex). Cells use their own small RNA duplexes as a form of gene regulation. These novel 
molecules have enormous therapeutic potential and at present there are close to 20 
compounds which have reached clinical trials (18). 
2. Ocular diseases addressable by nucleic acid–based drugs 
2.1. Glaucoma 
Glaucoma is the second leading cause of blindness globally (19). By year 2020 almost 80 
million people are estimated to be affected by primary open-angle glaucoma (POAG), the 
most common type of glaucoma. Glaucoma is defined as the process of ocular tissue 
destruction caused by a sustained elevation of intra ocular pressure (IOP) above its normal 
physiological limits (20). In open angle glaucoma (OAG), elevated IOP causes a progressive 
optic neuropathy due to loss of retinal ganglion cells that ultimately leads to blindness (21). 
In angle-closure glaucoma the sudden high rise in IOP often renders the eye blind. 
Blindness in glaucoma is caused by a degenerative process of the retina and optic nerve, but 
is functionally associated with impairments in the balance between aqueous humor (AH) 
secretion and outflow. Mechanistically, the changes observed in the trabecular meshwork 
include loss of cells as well the deposition and accumulation of extracellular debris 
including protein plaque-like material (22). The loss of vision is not usually evident until 
significant nerve damage has occurred. For this reason, up to half of glaucoma sufferers are 
unaware of their condition. Because of this, early diagnosis and treatment is crucial in 
halting the progression of this pathological condition (23). Risk factors associated with 
glaucoma include high intraocular pressure, advanced age, family history of glaucoma, 
African ancestry myopia, hypertension, morphologic features of the optic disc, thinness of 
the cornea, eye trauma, concomitant use of drugs, diabetes mellitus, hypothyroidism, 
cardiovascular and haematological abnormalities (24-28). Treatment of glaucoma is mainly 
focused on lowering IOP. The first line of treatment is medication, followed by surgical and 
laser treatment. Pharmacological compounds for treating glaucoma fall into four main 
classes of drugs: parasympathomimetics, antagonists of α and β-adrenoreceptors, inhibitors 
of carbonic anhydrases and prostaglandin analogues. Clinicians prescribe medications in a 
stepwise manner to achieve the target goal of IOP and maintain a balance between 
medication effectiveness, tolerability and safety. Beta blockers and prostaglandins are the 
standard first line treatment for POAG (29). Both groups of drugs are very efficient in 
lowering IOP but beta blockers are not recommended in patients with cardiovascular and 
respiratory problems and prostaglandin-analogs have local tolerability issues (30, 31). 
Second-line drugs of choice include alpha-2-adrenergic agonists and carbonic anhydrase 
inhibitors. When IOP is not adequately regulated with monotherapy it is common to 
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combine different antiglaucoma drugs, these combinations appear to have the advantage of 
greater efficacy, better cost and safety, but limit the individualization of dosing. The efficacy 
of current IOP-lowering therapies is relatively short lived, requiring repetitive dosing 
throughout the day and in some cases the efficacy decreases with time. Such negative effects 
may lead to decreased patient compliance or to the end of treatment. If no efficacy in 
reducing IOP is achieved with any of these drugs, laser therapy may be applied to the 
trabecular meshwork in order to increase AH outflow. The last therapeutic resource is 
surgical intervention to create a new route for AH outflow (32).  
Novel nucleic-based therapies seek improving the limitations of current antiglaucoma 
treatment. These are the goals pursued by Sylentis’ SYL040012, an siRNA-based drug for the 
treatment of glaucoma, currently in phase II clinical trial. SYL040012 is a chemically 
synthesized double-stranded oligonucleotide, specifically designed to target and inhibit 
synthesis of 2-adrenergic receptors. The compound has proven efficacious in inhibiting the 
expression of its target in cell cultures and in lowering IOP in normotensive and 
hypertensive rabbits (Martínez et al, unpublished results). The efficacy of SYL040012 in 
reducing IOP is similar to that of commercially available drugs (34). On the other hand, 
when commercial drugs are used, sustained reduction of IOP relies on the continuous 
application of the drugs. This is not the case with SYL040012, whose effect in animal models 
not only lasts 15 times longer than the effect of current treatments, but is also able to 
maintain the reduction in IOP levels even when the compound is not administered for a 
period of up to 72 hours. This feature is very attractive since it would protect against the 
eventual optic damage caused by a reboot effect on IOP in case of poor compliance with the 
treatment. Moreover, SYL040012 is stable up to 24 h in rabbit aqueous humour, but stability 
rapidly decreases in rabbit serum. The stability properties of SYL040012 support the use of a 
siRNA-based therapeutic approach for glaucoma since the compound should be stable 
enough to exert its effect in the eye but should be rapidly degraded when reaching general 
circulation, hence anticipating low systemic side effects.  
Using a completely different approach, Quark pharmaceuticals is developing QPI-1007, a 
synthetic chemically modified siRNA designed to temporarily inhibit the expression of the 
pro-apoptotic protein Caspase 2. QPI-1007 is currently undergoing clinical trials for optic 
nerve atrophy and non-arteritic ischemic optic neuropathy, but the company has expressed 
interest in developing adequate delivery systems for the potential use of this drug as a 
neuroprotectant for glaucoma (35).  
2.2. Age-Related Macular Degeneration (AMD) 
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the 
Western world, it occurs primarily among individuals over 50 years of age (36). AMD was a 
rare disorder in the 19th century but increase in life expectancy together with changes in 
life-style have enormously affected the prevalence of this disease (37). According to the 
2005-2008 National Health and Nutrition Examination Survey 6.5% of the US population 
over 40 years of age had signs of AMD (38). Extensive epidemiologic and genetic studies 
indicate that development of AMD is the result of a combination of several aspects such as 
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genetic predisposition and environmental factors. Tobacco smoking seems to be the most 
consistent and modifiable risk factor (39). Other risk factors include hypertension, 
cardiovascular disease and high body mass index (40). Among the genetic factors that confer 
susceptibility to developing AMD are variants in several genes encoding complement 
pathway proteins (41).   
The underlying cause for AMD seems to be accumulation of residual material produced by 
the renewal process of the external part of the photoreceptors of the retina in the retinal 
pigment epithelium (RPE). The accumulation of this undegraded material, known as drusen 
in the RPE leads to production of inflammatory mediators that cause photoreceptor 
degeneration in the central retina, or macula (42). The center of the macula, named fovea, 
mediates high acuity vision; hence its degeneration causes severe vision loss. In the early 
stages of the disease the accumulations of drusen are small and often observed along with 
hypo- or hyperpigmentation of the RPE. As the disease progresses both the size and the 
amount of drusen increase. Advanced AMD is characterized by the presence of large or 
several medium size drusen and loss of central vision and can take two forms: dry or wet. 
The dry form is characterized by a sharply delineated area of RPE atrophy along with loss of 
photoreceptors and changes in pigmentation of the RPE. In the wet form, or choroidal 
neovascularisation (CNV), fragile blood vessels of the choriocapillaris grow into the RPE 
and frequently leak blood and fluid that accumulate between RPE and the choriocapillaris. 
As a result of these abnormal growths, dense scars are formed in the macula.  Detachment of 
the RPE is also a frequent feature of this form of AMD. The wet form is more severe than the 
dry form and sometimes dry AMD can develop into wet AMD. 
Great advances have been made in recent years in the treatment of wet AMD; on the other 
hand treatment options for dry AMD are currently limited to dietary supplements and life-
style changes. Several pharmaceutical companies are developing compounds for dry AMD 
by targeting different aspects of the physiopathological progress of the disease. As 
mentioned above, inflammatory mediators are generated during the process leading to dry 
AMD, for this reason it has been suggested that antioxidants may play a role in minimizing 
progression of the disease. The Age-Related Eye Disease Study (AREDS) demonstrated that 
oral supplementation of antioxidants in patients with unilateral intermediate or advanced 
AMD reduced vision loss by 19%. In addition these patients showed a decrease of 25% in 
the chances of developing AMD in the other eye (43, 44).  
Other therapeutic approaches for dry AMD currently in clinical development are aimed 
towards reducing the accumulation of toxic metabolites, diminishing activation of the 
complement system or avoiding loss of neurons in the retina using neuroprotectants.  
As of March 2012 there were approximately 10 clinical studies for pharmaceuticals under 
development to treat dry AMD registered at www.clinicaltrials.gov with status “recruiting” 
or “active”. Among these clinical trials, only one is using an oligonucleotide based approach 
to treat dry AMD. ARC1905 is a pegylated aptamer that is currently in phase I study 
sponsored by Ophtotech Corporation. This compound antagonizes the cleavage of 
complement component C5 into C5a and C5b, thus inhibiting complement activation. 
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ARC1905 has shown to be safe when administered by intravitreal injection in combination 
with ranibizumab for wet AMD (45).  
Perhaps one of the facts preventing more oligonucleotide based therapies being developed 
for dry AMD is that doublestrand RNAs as short as 21 base pair are able to bind and 
activate Toll Like Receptor 3; and activation of this receptor has been associated with 
progress of dry AMD (46, 47).  
Wet AMD is characterized by the invasion of leaky blood vessels into the RPE. This 
mechanism is mediated by the action of vascular endothelial growth factor (VEGF). The 
biological activity of this growth factor has been the target of several therapeutic strategies 
in the past few years and the pharmaceuticals developed under these programs are the 
current first line treatment for wet AMD.  
Pegaptanib sodium (Macugen) is a 28-base pegylated aptamer designed to target VEGF 
(48) by Gilead Pharmaceuticals, licensed to Eyetech Pharmaceuticals/OSI. This drug was 
approved by the FDA in December 2004 for the treatment of all subtypes of wet AMD by 
intravitreal injection every six weeks. Pegaptanib specifically binds to VEGF165, the most 
pathogenic of the four isoforms of VEGF that are generated by alternative splicing of a 
common mRNA. The union of pegaptanib to VEGF prevents activation of either of the two 
receptors for VEGF (VEGFR-1 and VEGFR-2) present on the surface of epithelial cells; hence 
inhibiting its biological activity. The VEGF Inhibition Study in Ocular Neovascularizations 
trial demonstrated that pegaptanib sodium injection reduced the risk of moderate vision 
loss from 70% to 55% and of severe vision loss from 22% to 10% without serious systemic 
effects and a low rate of serious ocular adverse events (49).   
In July 2006 the second drug based on anti-VEGF therapy was approved by the FDA. 
Ranibizumab (Lucentis) is a recombinant, humanised, monoclonal anti-VEGF antibody 
fragment with high affinity for all isoforms of VEGF developed by Genentech that is 
administered by intravitreal injection. Two clinical trials (MARINA and ANCHOR) support 
the safety and efficacy of ranibizumab for wet AMD (50, 51).  The results of these trials 
showed that almost 95% of patients receiving the drug avoided moderate visual loss versus 
the 62.2% that managed to do so in the control group (receiving veteporfin). In addition, 
ranibizumab was not only able to stall progression of wet AMD but even to improve visual 
acuity in 35.7% of the patients treated with the low dose and in 40.3% of the patients treated 
with the high dose.   
The third anti-VEGF compound currently used in the clinic for treatment of wet AMD is 
bevacizumab (Avastin). Bevacizumab is a full-length monoclonal antibody that binds to 
and inhibits all isoforms of VEGF also developed by Genentech. Bevacizumab is in fact the 
full length antibody that was modified to develop ranibizumab. Ranibizumab was 
developed because preliminary results indicated that the size of the full length antibody 
would not allow for appropriate distribution within the retina. Additionally, the longer half 
life of bevacizumab raised concerns in terms of systemic toxicity. Bevacizumab is currently 
approved for the treatment of metastatic colorectal cancer and several other malignancies, 
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and it is used off-label for wet AMD (52). The reduced cost of bevacizumab compared to 
ranibizumab has extended the off-label use of this drug, for this reason several clinical trials 
have started in the last four years in order to gather evidence on the efficacy of bevacizumab 
in wet AMD (53, 54).  
In addition to pegaptanib, several other attempts have been made to treat wet AMD with 
oligonucleotides. Bevasiranib was the first small interfering RNA agent developed for this 
condition. Developed by OPKO Health, this agent is a naked 21-nt siRNA designed to target 
VEGF administered by intravitreal injection (55). The results of clinical trials conducted for 
phases I and II were positive and OPKO Health initiated a phase III clinical trial to examine 
the safety and efficacy of the combination of bevasiranib with ranibizumab. In March 2009 
OPKO terminated the phase III trial because the primary endpoint was not likely to be met: 
improved efficacy over ranibizumab.  
Following the same VEGF-inhibition strategy Sirna Therapeutics (now Merck) developed 
Sirna-027; a modified siRNA that targets one of the receptors for VEGF, VEGFR-1 (56). In 
vivo studies demonstrated that Sirna-027 was able to reduce the mRNA and protein levels 
of VEGFR-1 and to reduce the areas of neovascularation in a mouse model of ischemic 
retinopathy. An inverted sequence with the same chemical modifications as Sirna-027 was 
used as control and was shown not to have an effect on any of the parameters analysed (56). 
The control used in this study demonstrated that the effect of Sirna-027 was sequence 
specific; this was relevant due to the controversy generated by the results of a study 
published in 2008 that stated that angiogenesis could be suppressed by 21-nt siRNAs in a 
sequence-independent manner via TLR3 (57). Further clinical development of Sirna-027 was 
sponsored by Merck in collaboration with Allergan but, again, clinical trials for this 
compound were halted because the primary endpoint of efficacy trials was not met.   
Using a different strategy Quark developed PF-655, now developed in collaboration with Pfizer, 
a 19-nt 2’O-methyl-stabilized siRNA designed against RTP801, a newly discovered target that is 
rapidly and sharply upregulated in hypoxia and promotes apoptosis of neural cells (58, 59). In 
addition to its anti-apoptotic effect, this compound cooperates with VEGF inhibitors to reduce 
retinal neovascularisation. Although full results of the clinical trial have not yet been made 
public, in March 2011 Quark announced that their compound was not superior to ranibizumab, 
thus expectations for the phase IIb initiated by Quark alone are somewhat low.  
With two of the candidates already halted and a third most likely to be so, the fate of 
siRNAs in AMD is at least uncertain. Reports supporting that siRNAs 21 nt or longer 
activate TLR3 have certainly had a say in the matter. Activation of TLR3 in the RPE seems to 
induce RPE cell death and contribute to development of dry AMD (47), therefore tackling 
any form of AMD with double stranded RNA has to be achieved with shorter compounds 
and target specificity should be thoroughly studied.  
2.3. Diabetic retinopathy 
Diabetic retinopathy (DR) is a microvascular complication secondary to diabetes mellitus 
that leads to structural and functional changes in the retina, this complication is the leading 
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cause of visual loss in working-age individuals (60). The overall prevalence of this 
complication among individuals with diabetes is 34.6% (61) and it accounted for 2.4 million 
cases of blindness worldwide in 2002 (60). Hyperglycemia is a decisive factor in the 
development of DR because of its damaging effects per se; it also serves as a biomarker for 
control on the disregulation of metabolism that occurs in diabetes.   
In the initial phases of DR the vessels that irrigate the retina show microaneurysms and 
small leakages, this initial step of the disease is frequently referred to as nonproliferative 
DR. The changes observed in this phase are result of thickening of the capillary basement 
membrane as well as apoptosis and migration of pericytes. As the disease progresses the 
capillaries become permeable due to loss of interaction between endothelial cells and 
pericytes, and eventually macular edema can develop due to accumulation of fluids in the 
macula. The progressive occlusion of capillaries in the retina leads to tissue ischemia. As a 
result of the hypoxia caused by ischemia angiogenic factors such as VEGF are upregulated 
and capillaries grow into the retina, this stage is also known as proliferative DR (62). The 
new veins formed in response to the changes seen in the diabetic retina are fragile and 
permeable and some of them can break through the optic nerve leaking into the vitreous 
cavity or into the preretinal space. The process of neovascularisation is also associated with 
accumulation of a fibrous component that when contracted can lead to retinal detachment 
severely impairing vision (63).  
Currently, the gold-standard for treating DR is laser photocoagulation (64); this procedure 
seeks to mitigate damage but has no effect on the underlying causes of the disease. In 
addition, steroids can be intravitreally administered into the eye to reduce accumulation of 
fluids within the retina. Sometimes, the accumulation of blood in the vitreous humour can 
physically impede laser photocoagulation; in these cases a vitrectomy can be performed in 
order to remove the blood accumulated in the vitreous prior to laser photocoagulation.  
As mentioned previously, the action of angiogenic factors plays an important role in the 
development of DR. In this sense, several VEGF-inhibitors currently used for the treatment 
of AMD, are being studied for DR (see section 2.2 for details). Most of them are in late 
clinical trials and are expected to reach market authorization shortly.  
In the oligonucleotide-based field, some of the compounds initially developed for AMD 
have undergone clinical trials for different forms of diabetic retinopathy as well. Opko 
Health’s bevasiranib is one of these cases. A phase II clinical trial for diabetic macular edema 
was completed in 2008, and although positive results were reported, further development 
has not been announced. iCo Therapeutics is using a different approach with their lead 
compound iCo-007. iCo-007 is a chemically modified ASON inhibiting c-raf; a downstream 
mediator of several growth factors, including VEGF. In 2011 a phase II clinical trial was 
started for diabetic retinopathy in which two different doses of iCo-007 are to be assayed, 
either as a monotherapy or in combination with ranibizumab or laser photocoagulation. 
Preliminary results of this trial are expected in the second half of 2012. Another antisense 
alternative is being developed by Antisense Therapeutics, in this case a novel antisense 
compound ATL1103 which targets growth hormone receptor and has successfully 
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completed a phase I clinical trial. This compound is being developed for treatment of 
acromegaly and also diabetic retinopathy (65). 
2.4. Dry eye pain  
Dry eye disease (DED) or keratoconjunctivitis sicca (KCS) is a multifactorial ocular condition 
resulting from tear film instability that can eventually lead to ocular surface damage. 
Typical symptoms of DED include ocular discomfort, visual disturbance, itching, burning, 
sensation of foreign body, light sensitivity; inflammation and pain. Factors contributing to 
DED are insufficient tear secretion; excessive evaporation and alteration in the composition 
of the tear film. The tear film has three essential components: aqueous layer, secreted by the 
lachrymal glands; mucus layer, produced by the globet cells of the conjunctiva and by 
epithelial cells of the cornea and conjunctiva and finally a lipid layer, secreted by the 
meibomian glands. Changes in the tear film can be temporary causing an acute form of DED 
or long-lasting leading to chronic DED; damage to the ocular surface is usually more severe 
in the chronic forms than in the acute ones. DED is frequent in some conditions such as 
Sjögren’s disease, or lachrymal gland dysfunction, but it can also be caused by vitamin 
deficiency, contact lens wear and use of several prescription drugs. As such, it is not 
surprising that DED is a very frequent condition; the prevalence varies tremendously 
depending on the study, and the condition is more frequent in patients with autoimmune 
diseases, postmenopausal women and elderly population (66).  
Treatment of DED depends on the etiology of the condition. The first line treatment is 
usually use of lubricants such as artificial tears and avoidance of preservatives such as BAK 
if other eye treatments are required. Other treatment options include procedures that favour 
tear retention: punctal occlusion, moisture chamber spectacles and contact lenses; 
pharmacologic agents that stimulate tear secretion or anti-inflammatory therapy. 
Although some advances have been made towards alleviating some of the symptoms of 
DED, pain associated to this condition is not usually addressed. Sylentis is currently 
developing an siRNA, SYL1001, for the treatment of pain associated to DED. The compound 
targets TRPV1, a very well known target for pain, which is highly expressed in the cornea 
and trigeminal ganglion. SYL1001 is applied in eye drops, contains no preservatives and has 
recently shown favourable local and systemic tolerance results in a phase IA study. 
2.5. Corneal neovascularitation associated with corneal graft rejection 
Optimal vision is contingent upon transparency of the cornea. Corneal neovascularization, 
trauma and surgical procedures such as photorefractive keratectomy and graft rejection 
after penetrating keratoplasty (PKP) can lead to corneal opacification (67). Corneal 
neovascularization, regardless of the underlying cause, leads to decreased vision, recurrent 
corneal erosion, and incompetent barrier function thus presenting a serious clinical problem 
for which treatment is poor (68). When transparency of the native cornea cannot be 
maintained at a functional level corneal transplantation is often the next intervention. Once 
transplanted, the major cause of corneal graft failure is allograft rejection. Despite this fact, 
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corneal transplantation has a very high success rate. Over 90% of low-risk corneal 
transplants retain clarity years after transplantation using only local immunosuppression. 
Blocking access of the host immune system to the donor cornea is the first line of defense 
against corneal allograft rejection, of which corneal avascularity is an essential component. 
Corneal graft rejection is primarily a cell-mediated immune response controlled by T cells 
(69). Normal corneal immune privilege can be eroded by neovascularisation, especially if it 
is accompanied by ocular inflammation and increased intraocular pressure. New vessels 
generated by neovascularisation provide a route of entry for immune-mediating cells to the 
graft, while the growth of new lymphatic vessels enables the exit of APCs and antigenic 
material from the graft to regional lymph nodes. The cornea consequently becomes 
infiltrated with and sensitized to immune reaction mediators. Therefore, neovascularisation 
may induce an immune response that can lead to immunological corneal graft rejection (70, 
71). In normal low risk grafts it is a general practice to avoid exposing suture knots and ends 
which may stimulate neovascularization, and to treat neovascularization aggressively using 
topical steroids (67).  
Due to the crucial role of VEGF in neovascularisation (see section 2.2), many have suggested 
that VEGF inhibition may prevent corneal transplant rejection. Despite the efforts made in 
recent years on the use of anti-VEGF compounds for corneal rejection it is still not clear 
whether the treatment is adequate (72, 73).  
Several nucleic-based therapies are currently being developed with the hope of filling this 
uncovered therapeutic gap. Although the molecular mechanisms that control 
neovascularization are not well understood, inflammation has been found to frequently 
precede corneal neovascularisation. For this reason, many studies have concentrated their 
efforts on targeting humoral and corneal-derived inflammatory mediators. Among these 
mediators are arachidonic-acid derived eicosanoids of the cytochrome P450 monooxygenase 
(CYP) pathways. Seta and collaborators designed specific siRNAs targeting CYP4B1a, 
CYP4B1b and CYP4B1c and demonstrated that silencing the expression of CYP4B1 
diminished corneal vascular response and greatly attenuated VEGF mRNA levels in an 
animal model of inflammatory neovascularization (68). One of the most advanced nucleic-
based therapies is GS-101 (Aganirsen). GS-101, developed by the Swiss company 
GeneSignal, is a 25-mer phosphorothioate ASON that inhibits the expression of Insulin 
Receptor Substrate-1 (IRS-1). IRS-1 is a cytoplasmic adapter protein without intrinsic kinase 
activity. The main function of this protein is to recruit other proteins to their receptors and 
induce the organization of intracellular signalling cascades (74). IRS-1 interacts with the 
VEGF-receptor complex in angiogenesis (75) and it promotes lymphangiogenesis by 
interacting with integrins (76, 77). Downregulation of IRS-1 results in prevention of 
neovascular growth and has been reported to prevent the angiogenic process in preclinical 
in vivo and in vitro experiments (78, 79). Phase I clinical studies demonstrated excellent 
safety and tolerability of GS-101 when applied as eyedrops three times a day. In April 2007 
the EMA granted orphan drug designation for GS-101 for the treatment of corneal graft 
rejection associated to corneal neovascularisation. After successfully completing a phase II 
trial GS-101 is about to enter phase III clinical trials (80).  
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2.6. Ophthalmic infections 
There are several sight-threatening diseases caused by viral infections. Infections caused by 
virus imply the use of the cellular machinery by the virus to replicate. Hence, all infected 
cells will have foreign nucleic acids encoding viral specific proteins inside them. Given that 
oligonucleotide based therapies pursue downregulating expression of genes it seems 
obvious to target viral specific genes. In the following section several approaches using this 
rationale will be explained focusing on antivirals developed for treating viral infections in 
the eye. The first success case of oligonucleotide-based therapies came precisely in this field, 
fomivirsen was the first compound based on oligonucleotides to be approved by the FDA.  
Citomegalovirus-induced retinitis is among the most common opportunistic infections in 
severely immunocompromised patients (81). In AIDS patients, CMV infection is associated 
with gastrointestinal disorders and retinitis. An estimated 15 to 40% of AIDS patients will 
suffer CMV-induced retinitis. This condition if left untreated leads to blindness within six 
months (82). Three systemic compounds are available for the treatment of this disease: 
ganciclovir, foscarnet, and cidofovir. The mechanism of action of these three compounds is 
inhibition of the CMV DNA polymerase. However, these treatments have some drawbacks 
such as limited efficacy, poor oral bioavailability, toxicity and emergence of multidrug 
resistant strains due to mutations in the target gene (83). Because of this, effective therapy 
usually implies alternation between the three available antivirals or different combinations 
of them, along with intraocular drug injections. This approach, known as highly active 
antiretroviral therapy (HAART), reduces 55%-95% the number of new cases of CMV (81). 
Without acute therapy, retinitis spreads throughout the entire retina causing total retinal 
destruction and blindness; without chronic suppressive maintenance therapy relapse of the 
retinitis occurs promptly (84). Looking for an alternative approach Isis Pharmaceuticals Inc. 
developed an ASON that targets the immediate-early (IE) gene of human CMV. Fomivirsen, 
(Vitravene®) is a phosphorothioate oligonucleotide (ISIS-2922) developed by Isis in 
partnership with CIBA vision, for the treatment of newly diagnosed and advanced CMV 
retinitis in AIDS patients and was the first oligonucleotide based drug approved by the FDA 
in 1998. Administered by intravitreal injection it has shown good clinical activity against this 
disease (85).  
Acute Retinal Necrosis (ARN) is a type of retinitis that affects both healthy and immuno-
compromised patients (86). This inflammatory disease is caused by several members of the 
herpesvirus family including herpes simplex virus (HSV-1), varicela zoster virus (VZV) 
and citomegalovirus (CMV) (87, 88). The disease usually starts with signs of uveitis: red 
eyes, light sensitivity, eye pain and blurred vision. Detailed examination of the eyes of 
these patients show infiltration of inflammatory cells in the anterior and posterior 
segments in all retinal layers (89). As the disease progresses retinal necrosis and occlusive 
arteriolar retinopathy are found. Current treatment for this condition includes antiviral 
therapy and topical cortosteroids (89). There is no treatment that can prevent the 
establishment or persistence of latent infection. Reactivation of HSV-1 infections, are 
currently controlled clinically with long term administration of acyclovir or its derivatives. 
 
Ocular Diseases 168 
Antiviral drugs can quell symptoms resulting from reactivation outbreaks but cannot 
eliminate latent virus. Furthermore, long-term usage of antiviral drugs can lead to 
development of drug-resistant viruses (90). Several authors have designed specific ASON 
targeting the proinflammatory cytokine tumor necrosis factor alpha (TNF) (91, 92). TNF 
is known to possess many cell-activating and proinflammatory activities. TNF mRNA 
and protein are up-regulated in eyes infected with HSV-1 (93). Moreover, experiments 
using DNA microarrays have shown that TNF and its receptors are upregulated in eyes of 
mice with HSV-1 retinitis (94). The results of these experiments show that either 
intravitreal or subconjunctival injections of TNF-ASON provide local therapeutic effects 
without systemic adverse effects. Another strategy uses morpholino oligomers specifically 
designed to reduce viral mRNA trough steric blocking. Moerdyk-Schauwecker and 
collaborators have developed five phosphoro- diamidate morpholino oligomers (PMO) 
that target three HSV-1 genes: ICP0, ICP4 and ICP27. Their experimental results 
demonstrated that PMO targeting HSV-1 mRNAs not only inhibited viral replication in cell 
cultures but also in mouse models of the disease (90).  
HSV-1 not only causes ARN it is also responsible for Herpetic Stromal keratitis (HSK) a 
well- defined immune mediated blinding corneal disease (95). There is profound evidence 
that the corneal inflammation in HSK is orchestrated by CD4+ T cells and is accompanied 
by uncontrolled development of blood vessels within the eye (96). The corneal infiltration 
contains abundant polymorphonuclear cells. These cells, although important for 
controlling virus replication, are also responsible for damage to the cornea (97, 98). Due to 
the relevant role of TNF- and IFN in the progress of HSK, targeting TNF- and IFN has 
been proposed as a therapeutic approach (99). Wasmuth and collaborators demonstrated 
that topical administration of ASONs targeting either TNF- or IFN were capable of 
reducing their target in mice infected by HSV-1 without altering antiviral immune 
response (100, 101). In addition to the production of proinflammatory cytokines, 
neovascularization of the cornea is observed in this pathogenesis. As in other diseases in 
which neovascularisation plays a role, VEGF seems to be at least in part, responsible for the 
process. Validation of this theory has been performed by inhibiting HSV induced 
angiogenesis in mice with either a VEGF neutralizing antibody or an siRNA designed 
against this target (102).  
Acute Hemorrhagic Conjuntivitis (AHC) is a highly contagious eye disease caused primarily 
by enterovirus 70 (EV70) or coxackievirus A24 (CVA24) infection. Thus, several authors 
attempted to develop novel siRNA-based anti-AHC agent effective against both EV70 and 
CVA24. Resulting siRNAs showed excellent cytoprotective effects and dramatic decreases in 
viral replication and protein synthesis in primary human conjunctival cells, MRC5 and 
HeLa cells (103) or in Rabdomyosarcoma cells (104).  
2.7. Chronic optic nerve atrophy and ischemic optic neuropathy 
Ischemic optic neuropathy is defined as vision loss due to lack of blood supply to the optic 
disc (infarction). Decreased visual acuity and visual field are usually the only symptoms of 
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ischemic optic neuropathy regardless of the underlying cause. Ischemic optic neuropathy is 
primarily of two types: Anterior (AION) and posterior (PION) involving the optic nerve 
head (ONH) and the rest of the optic nerve, respectively (105). AION can be arteritic (A-
AION) and non-arteritic (NA-AION). In the management of AION, it is crucial to identify 
the form of AION. A-AION is an ophthalmic emergency and requires urgent treatment with 
high-dose steroid therapy to prevent further visual loss to both the affected eye and the 
sometimes asymptomatic Contralateral eye. NA-AION is the most common form of the 
disease and it is usually detected due to unilateral painless visual loss along with edema to 
the optic nerve. It is more frequent in patients between 40 and 70 years of age and vision 
loss is usually less severe than in the A-AION. Systemic risk factors particularly nocturnal 
arterial hypotension, play major roles in the development of NA-AION. NA-AION patients 
treated with high doses of systemic steroid therapy showed significant improvement in 
visual acuity and visual field. (106).  
Given that the loss of vision in these conditions is due to loss of retinal ganglion cells (RGC) 
neuroprotection seems a rational approach. Focusing on this line of thought, Quark 
Pharmaceuticals is currently developing a nucleic-acid based therapy, specifically a siRNA-
based therapy: QPI-1007. QPI-1007 is a synthetic siRNA designed to temporarily inhibit 
expression of the pro-apoptotic protein caspase 2 that is currently in clinical trials for the 
treatment of NA-AION. Ahmed and colleagues in collaboration with Quark 
pharmaceuticals have shown that caspase-2 contributes loss of RGC in rat models of the 
condition and have demonstrated that intravitreal injections of QPI-1007 are effective in 
protecting against the death of RGC (35). Quark Pharmaceuticals is conducting a Phase I- 
dose escalation safety study using QPI-1007 in patients suffering from Optic Nerve Atrophy 
and NA-AION. Caspase 2 isn’t the only interesting target that offers a potential avenue for 
treatment in optic neurophaty. Helen and collaborators have focused on the action of 
another protein: connexin 43 (Cx43). Preclinical results show that an ASONs designed to 
specifically reduce upregulated levels of Cx43 in a model of optic ischemia has therapeutic 
potential (107) 
2.8. Inherited ocular diseases: Retinitis Pigmentosa (RP) and  
Ocular Albinism (OA) 
Retinitis pigmentosa (RP) is a class of diseases involving progressive degeneration of the 
retina and a leading cause of inherited blindness. RP is a heterogeneous disorder that starts 
in mid-periphery and advances towards the macula and fovea. Typical symptoms include 
night blindness followed by decreasing visual field, leading to tunnel vision and eventually 
legal blindness or in many cases complete blindness (108). This disorder involves 
photoreceptor-cell degeneration and affects ~ 1 in 3000 people (109). On the cellular level the 
rod photoreceptor system is predominantly affected but in later stages of the disease cone 
photoreceptors can also be affected (108). More than 40 causative genes have been 
implicated in RP, although mutations in rhodopsin gene (RHO) account for 15% of all types 
of RP. Great efforts have been made to explore new gene therapies for RP, but inter and 
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intragenic heterogeneity represent significant barriers to therapeutic development. For 
example more than 100 mutations in the human RHO gene, which encodes the 
photosensitive pigment in rod photoreceptors, have been identified in autosomal 
dominantly inherited RP (110). Development of therapies for each individual mutation 
would be technically difficult to achieve and not economically viable; thus a therapeutic 
approach that circumvents mutational diversity would be of great value. At present, there is 
one treatment which has reached the clinic for the treatment of Leber’s congenital amaurosis 
form 2 (LCA2), a type of RP, based on adenoviral (AAV) delivered gene therapy. Three 
years ago, Maguire and colleagues reported results in 12 patients who were treated with 
gene-replacement therapy. LCA2 is associated with mutations in RPE65, which encodes a 
protein requisite for the isomerohydrolase activity of the retinal pigment epithelium. This 
activity produces 11-cis-retinal, the natural ligand and chromophore of the opsins of rod and 
cone photoreceptors, the opsins cannot capture light and transduce it into electrical 
responses to initiate vision. In this study patients received one subretinal injection of AAV2-
hRPE65v2 (a viral vector encoding RPE65 protein). Visual improvement was observed in all 
12 patients with the greatest gains among younger patients (111). 
Still in early research stages are different approaches to the treatment of RP based on the 
administration of AAV-delivered RNA interfering compounds. Amongst these, both the 
University of Florida and Smurfit Institute of Genetics have achieved interesting results in 
vivo by silencing the expression of RHO in mouse models (112). More recent studies by Jiang 
and collaborators show how using  an AVV2/8 vector to develop an RNAi-based therapy in 
a dominant retinal degeneration mouse model expressing bovine GCAP1 (Y99C), 
significantly improved photoreceptor survival, delaying disease onset and increasing visual 
function (113). There are also several studies that target inosine 5’-monophosphate 
dehydrogenase 1 (IMPDH1) with viral delivered siRNA for the treatment of RP10 form of 
autosomal dominant RP(114). Another interesting approach based on RNAi therapy uses 
siRNAs to facilitate transplantation of rod photoreceptors, by disrupting junctional proteins 
and enhance donor cell integration in the retina (115). 
Ocular albinism type 1 is a group of X-linked or autosomal genetic disorders characterized 
by partial or total lack of melanin pigmentation in the eyes due to mutations in genes 
encoding proteins involved in melanogenesis. Eyes may be severely affected with 
photophobia and reduced visual acuity. Nystagmus or strabismus, are often associated and 
the irides and fundus are depigmented. Many forms of albinism, more or less severe, have 
been described. Some forms also affect skin and hair. As in other forms of albinism, these 
patients suffer loss of stereoscopic vision due to reduction of the ipsilateral component of 
the optic tract (116). General prevalence of albinism is 1/15,000 inhabitants. Treatment is 
exclusively symptomatic. Vetrini and collaborators have described an intronic point 
mutation in ocular albinism type 1 (OA1) gene in a family with the X-linked form of ocular 
albinism. Interestingly the mutation creates a new acceptor splice in intron 7 of the OA1 
gene leading to aberrant protein expression. In addition to low levels of normally spliced 
mRNA product of the OA1 gene, patient samples contained aberrant spliced mRNA. OA1 
expression was rescued in the patient’s melanocytes with an antisense morpholino modified 
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oligonucleotide (MO) complementary to the mutant sequence. The MO was able to rescue 
OA1 expression and restore the protein level in the patient’s melanocyte by skipping the 
aberrant inclusion (116). 
 
Compound Indication Company 
Type of 
compound 
Target Stage 
SYL040012 Glaucoma Sylentis Naked siRNA ADRB2 Ph II 
QPI-1007 
Glaucoma Quark 
Pharmaceuticals
Modified 
siRNA 
Caspase 2 
R&D 
NA-ION Ph I 
ARC1905 
Dry AMD 
Ophthotech 
Corporation 
Pegylated 
aptamer 
Complement 
component C5
Ph I 
Wet AMD (in 
combination with 
ranibizumab) 
Ph I 
E10030 
Wet AMD (in 
combination with 
ranibizumab) 
Ophthotech 
Corporation 
Aptamer PDGF Ph II 
Pegaptanib 
Wet AMD 
Eyetech/OSI 
Eyetech/Pfizer 
Pegylated 
aptamer 
VEGF 
Approved 
Diabetic Macular 
Edema 
Ph III 
Bevasiranib 
Wet AMD 
OPKO Health Naked siRNA VEGF 
Ph III (Term.) 
Diabetic Macular 
Edema 
Ph II 
Sirna-027 Wet AMD Merck/Allergan
Modified 
siRNA 
VEGF Ph II (Term.) 
PF-655 Wet AMD Quark/Pfizer 
Modified 
siRNA 
RTP801 Ph IIb 
iCO-007 
Diabetic Macular 
Edema 
iCO Therapeutics
Modified 
antisense 
c-raf Ph II 
ALT1103 Diabetic retinopathy 
Antisense 
Therapeutics 
Antisense GHR R&D 
SYL1001 Dry eye pain Sylentis Naked siRNA TRPV1 Ph I 
GS-101 
Corneal graft rejection 
associated to corneal 
neovascularization 
GeneSignal 
Phosphorothioa
te antisense 
IRS-1 Ph III 
Fomivirsen 
Advanced CMV 
infection in AIDS 
patients 
Isis/CIBA 
Phosphorothioa
te antisense 
IE gene CMV Approved 
Table 1. Compounds based on oligonucleotides under development for the treatment of ocular 
diseases. 
3. Safety issues 
3.1. Immunotoxicity 
As part of the defensive duties of the innate immune system it needs to discriminate 
between foreign and endogenous genetic material. Destruction of exogenous genetic 
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material is an essential part of protection against microorganisms, but can be a hurdle when 
trying to introduce synthetic genetic material for therapeutic purposes. The immune system 
responds to microbial RNA and DNA by producing type I interferon and proinflammatory 
cytokines. The chain reaction leading to production of these immune mediators is initiated 
by detecting conserved motifs of pathogens; this job is performed by several cell membrane 
and cytoplasmic receptors present at low levels in most cells. Toll-like receptors (TLR) are 
present in either the cell surface or in intracellular endocytic organelles and activation of 
these receptors leads to increase in the presenting capacity of dendritic cells and production 
of type I interferon. The TLRs responsible for detecting oligonucleotides are present 
exclusively in endosomes and are TLR3 that senses dsRNA (117), TLR7/8 that sense ssRNA 
(118) and TLR9 that senses ssDNA (119). TLRs are mainly expressed in immune cells; but 
foreign material has to be detected in non-immune cells as well; this task is performed by 
cytosolic sensor proteins. The dsRNA-dependent protein kinase (PKR) is a cytoplasmic 
sensor of RNA. Upon activation by binding to dsRNA, PKR forms a homodimer that 
acquires phosphorilation activity. Among the phosphorilation targets of PKR is eIF-2α; 
phosphorilation of this transcription factor leads translation inhibition and apoptosis (120). 
A second cytosolic sensor of dsRNAs is 2’-5’ oligoadenylate synthetase (OAS). Activation of 
this protein promotes the activation of ribonucleases that degrade endogenous and 
exogenous RNA, again leading the cell to apotosis (121). Other cytosolic sensors of dsRNA 
are the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) (122). RLRs are DExD/H 
RNA helicases. Two members of this family, RIG-I and MDA-5, have in addition to the 
helicase domain, two caspase activation and recruiting domains. Binding of dsRNA to RIG-I 
or MDA-5 activates a complex signalling cascade that ultimately leads to interferon-β 
production and apoptosis (123). As reviewed above, the immune system is prepared to react 
when foreign biological material is detected inside the body; several strategies can be used 
to bypass or modulate the response of the immune system:  
- Avoidance of sequence motifs or structures that are specifically recognized by the 
oligonucleotide sensors of the innate immunity. Lowering the number of uridines in a 
given RNA seems to lower the likelihood of an immune response; completely replacing 
the uridines by adenosines completely abrogates immune activation (124). Also, 
avoiding blunt ends on siRNAs could help reducing the immune response. RIG-I 
recognizes siRNAs with or without 2-base 3’ overhangs, but only those with blunt ends 
are able to trigger its ATPase activity and subsequent downstream signalling (125). 
- Introducing chemical modifications in nucleotides and/or their backbones to avoid 
activation of the immune response. 2’OMe and pseudouridine are modifications 
frequently present in mammalian RNAs; these modifications help avoiding triggering 
the immune response. Other modifications such as 2’F and LNA can also help evade 
immune detection (124). Whenever modifications are introduced into an 
oligonucleotide the modified molecule should be tested in order to make sure that the 
silencing activity has not been abolished. 
- Use targeted delivery of oligonucleotides (126) or delivery techniques that avoid the 
endosome routes for sequences that could activate TLRs.  Use of inhibitors of 
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endosomal maturation such as chloroquine and bafilomycin A1 can also abrogate the 
immune response (125). 
- Use of immunomodulators to impair or abolish the immune response.  
Some of the first therapeutic approaches using oligonucleotides were made in the field of 
ophthalmology. The eye is an immune privileged site, and this fact is one of the rationales 
behind the election of this site for the first trials. Several overlapping mechanisms 
contribute to establishing and maintaining immune privilege: the eye has a high content of 
immunosuppressive factors; it has a low expression of MHCII, hence limiting antigen 
presentation; stromal cells of the iris, ciliary body and retina are able to convert immune T 
cells to regulatory (Treg) cells, and retinal epithelial pigment cells are able to inhibit 
primed T cells; and finally death receptors such as FasL and PDL-1 are expressed by 
stromal cells that are able to induce apoptosis in immune cells that enter the eye (127).  
These advantages should not be interpreted as a free pass in terms of immunity for 
oligonucleotide therapies in the eye. In this regard, it has been shown that some siRNAs 
are able to activate TLR3 in a sequence-independent manner. Activation of this receptor by 
dsRNA has been found to suppress angiogenesis (57) and to induce retinal cell death; thus 
promoting atrophic AMD (46).  
3.2. Non immune off target effects 
The interaction of therapeutic oligonucleotides with their intended target RNAs is, with the 
exception of aptamers, highly sequence-specific. However, binding of one of these 
molecules to a non-target sequence requires only homology with a few base pairs. The result 
of this undesired interaction could be the inhibition of an unintended gene or an off target 
effect (OTE). Off-targeting is mostly mediated by the interaction between certain regions of 
the therapeutic molecule and complementary sites in the unintended target rather than 
overall homology between the two molecules (128). Careful comparison of candidate 
sequences with the entire transcriptome, attempting to avoid long stretches of homology, 
still remain necessary but are inadequate on their own to predict the actual risk of OTEs. 
Use of chemical modifications and improvement in oligonucleotide design has been 
successfully employed to reduce the likelihood of OTEs.   
The specificity of a sequence can be improved taking into account some important 
designing parameters such as thermodynamic stability of the duplex and 5’ and 3’-ends, 
the Tm value of the interaction region between the therapeutic oligonucleotide and 
possible off-targets (129) When dealing with knock down of mRNAs using siRNAs or 
antisense oligonucleotides the target position should be selected choosing regions that are 
as far away as possible from the initiation codon (130). The silencing effect of 
oligonucleotides is in general concentration-dependent, considerable success in reducing 
siRNA/antisense off-targeting has been achieved optimizing doses of the therapeutic 
oligonucleotide (131). Improvements in specificity achieved by altering sequences and/or 
introducing chemical modifications as well as in delivery of the molecule have also shown 
to have an impact on reducing potential off-target effects. Placing a 2’OMe at position 2 of 
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the guide strand  of a siRNA (132), or incorporating a destabilizing UNA at position 7 are 
examples of modifications that reduce OTEs (131).  
3.3. Oversaturation of endogenous RNAi-silencing complex (RISC) 
Bioactive drugs that rely on cellular processes to exert their functions face the risk of 
saturating endogenous pathways. This may be the case with RNAi-based drugs. Naturally 
occurring, small RNAs have undergone the process of evolution because of selection 
pressure and they exist in a perfect balance with their precursors and targets, as well as with 
the associated machinery involved in this process. Gene Silencing is performed by 
introducing artificially synthesized small RNAs into the cell or by expressing 
siRNAs/shRNAs within the cell, which enter the endogenous RNAi pathway at different 
levels. shRNAs and siRNAs are very similar to miRNA precursors before and after Dicer 
processing, respectively, relying on endogenous miRNA machinery to achieve target 
silencing. If the siRNA design parameters are not optimal they might cause an imbalance of 
the endogenous small RNA mediated pathways resulting in various and deleterious 
unwanted effects in the cells. It becomes therefore crucial to optimize the siRNA/shRNA 
design parameters and work at the lowest possible concentrations to mitigate the potential 
of side effects.  
4. Advantages of RNAi-based therapeutics and challenges ahead 
This new revolutionary technology presents many advantages for therapeutic development 
with respect to classical compounds, mainly: 
- They are based on an endogenous mechanism, thus involving the administration of a 
type of molecule already present in the cells, and hence, in principle, less hazardous: 
cells should have the capacity to handle resulting breakdown products. 
- As with antisense molecules before them, RNAi molecules can potentially address any 
pathological target, this means that even diverse intracellular molecules can be the 
object of these therapies. However, one must bear in mind that in practice, some genes 
are harder to target than others, and further more sophisticated algorithms must be 
developed to address this issue. 
- Also in comparison to antisense, RNAi is considerably more potent (133) and 
consequently may be used at lower concentrations. It is believed also to have a more 
persistent pharmacological action than traditional drugs because it blocks protein 
synthesis and hence, the cell will have to re-synthesise the protein from scratch to 
return to its previous state. Thus allowing the use of lower or less frequent doses. 
- Given the selectivity and specificity of these compounds, coupled with the fact of their 
in silico design and analysis they will have potentially less harmful side effects. 
- Another main advantage from an industry perspective is their much shorter 
pharmacological development, the estimate being 2-3 years vs 4-6 years from proof of 
concept. This can be attributed among other things, to the fact that the compound can 
be designed against homologous regions of the human gene sequence between the 
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different animal models used for preclinical studies, thus simplifying toxicology 
studies. 
- Finally, despite being novel entities they are easy to manufacture using a nucleotide 
synthesiser which simplifies large scale production. Additionally, this means the 
compounds are chemical entities rather than biological products, greatly helping the 
regulatory process for approval of these medicaments. 
Nevertheless, RNAi still has certain hurdles to overcome before its full potential can be 
exploited. The main obstacle is delivery of siRNAs to the desired tissue, and although many 
advances have been made in this area, much work still remains for therapeutic possibilities 
to be fully exploited. On the other hand, in a clinical setting, RNAi can only be used to treat 
pathologies caused by expression or overexpression of a given protein or by the presence of 
exogenous organisms, as its mechanism works through suppression of protein expression; 
i.e. it is only of use when the therapeutic option requires a loss of function. Furthermore, 
although any gene is a potential target for RNAi, in practice not all mRNAs are as easily 
silenced and new more sophisticated algorithms will need to be developed to overcome this 
issue. And last but not least, as discussed in the previous section the issue of off-target 
effects resulting from siRNAs silencing unwanted genes can lead to important safety 
considerations when developing new medicaments. 
From the perspective of ocular disorders, the eye is a relatively isolated compartment 
which makes it an ideal target organ for gene silencing. Local delivery of the compound to 
the eye limits exposure to the rest of the body and reduces the amount that is needed. 
siRNA injected into the vitreous cavity readily diffuses throughout the eye and is 
detectable for at least five days (56), the amounts used for intraocular injections are small 
compared to those used for systemic application and so as siRNA gets out of the eye it is 
diluted and is difficult to detect. This allows local silencing of a gene with little chance for 
an effect on the same gene outside the eye, reducing concern of remote effects in other 
tissues complicating observations in the eye. The sequence specificity of siRNA resulting in 
targeting of a single gene combined with local administration in the relatively isolated 
confines of the eye provides an ideal way to study eye-specific effects of gene disruption 
(34). While the development of siRNA-based therapies has promise for all tissues, the 
unique characteristics of the eye provide advantages which explain why the first siRNA 
compounds to advance through clinical trials were for the treatment of wet AMD, a disease 
affecting the back of the eye. 
5. Prospects for current therapies based on nucleic-based strategies 
The clinical progress of oligonucleotide drugs has been slow because realizing them requires 
inventing a new model for pharmaceutical development that allows large, highly charged 
molecules to be synthesized economically, distribute to target tissues, enter cells, and 
function within acceptable limits for toxicity. Oligonucleotides are large, unlike traditional 
small molecule drugs (<500-700 molecular weight), and much effort has been required to 
understand their properties and optimize them. However, considering RNAi was 
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discovered just over a decade ago, this technology has advanced towards clinical trials with 
amazing speed. Both for antisense molecules and RNAi compounds initial most advanced 
therapies were developed taking advantage of the environment within the interior of the 
eye. One antisense oligonucleotide has been approved by the FDA in 1998: Vitravene® or 
fomivirsen developed by Isis Pharmaceuticals for the treatment of cytomegalovirus retinitis 
in immunocompromised patients. Initial most advanced siRNAs were designed to treat wet 
age-related macular degeneration (AMD) taking advantage of the relatively RNAse free 
environment of the interior of the eye. These therapies were based on intravitreal injection, a 
form of administration which allows bypassing on of the main rate-limiting issues for 
therapeutic oligonucleotides, that of delivery to the required target tissue. 
Delivering oligonucleotides in whole organisms requires crossing many barriers. 
Degradation by serum nucleases, clearance by the kidney, or inappropriate biodistribution 
can prevent the oligonucleotide from ever reaching its target organ. Generally, the 
oligonucleotide must pass through the blood vessel wall and navigate the interstitial space 
and extracellular matrix. Finally, if the oligonucleotide succeeds in reaching the appropriate 
cell membrane, it will usually be taken up into an endosome, from which it must escape to 
be active. Antisense oligonucleotides are usually delivered in saline and rely on chemical 
modifications to enable uptake. Their phosphorothioate backbone binds to serum proteins, 
slowing excretion by the kidney (134). The aromatic nucleobases also interact with other 
hydrophobic molecules in serum and on cell surfaces; many types of cells in vivo express 
surface receptors that actively take up oligonucleotides.  
Delivery is even more challenging for siRNAs, where all the aromatic nucleobases are on the 
inside, leaving heavily hydrated phosphates on the outside of the duplex. This hydrated 
surface interacts poorly with cell surfaces and is rapidly excreted in the urine. Hence, except 
for direct injection in targets such as the eye where they are also delivered in saline, 
researchers have invested heavily in the development of delivery vehicles for siRNA. 
Various delivery strategies include nanoparticles, cationic lipids, antibodies, cholesterol, 
aptamers and viral vectors for short hairpin RNAs. In this case, the delivery system most 
clinically validated is that based on SNALP (stable nucleic acid lipid particle) technology 
developed by Tekmira for systemic administration of siRNAs. However, although it is being 
used to formulate at least 4 different siRNAs currently undergoing clinical trials, it has yet to 
be used more extensively before victory can be claimed on the battle of delivery.  
The field of oligonucleotide therapeutics has often swung from irrational optimism to 
irrational despair.  This is true for industry, but in the laboratory as well, gene knockdown 
experiments have fallen in and out of favour with researchers. In reality, oligonucleotides 
are useful tools with strengths and weaknesses (135). The promise of RNAi as a powerful 
new approach for therapeutic treatment of diseases has propelled early stage clinical testing 
of siRNAs for a variety of diseases. However, it is still too soon to evaluate whether or not 
RNAi based therapeutics will live up to their expectations. Given the mood swings in this 
area, with big pharma investing large sums in the technology at one point and then backing 
out only two or three years later, the industry has been in a turmoil which is now beginning 
to even out. This relative calm should bring about maturity in the field with the science 
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becoming more solid as we gain more knowledge of the biology of these compounds. From 
an industry perspective, it is foreseeable that Big Pharma’s involvement will continue the 
later trend of product-specific licensing and co-development rather than the purchase of 
platform technologies from smaller biotech experts performed in the early days of the 
technology. This is also in line with structural changes in the industry towards the 
outsourcing of research (136). 
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